Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
ConditionHeart Failure, Congestive
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age19+
SponsorHeart Center Research, LLC
About this trial
The DART-HA study is a single-center, open label, trial intended to evaluate the clinical efficacy of standard treatment options for congestive heart failure (observation, diuretic or afterload reduction therapy) in patients without new symptoms who have developed abnormalities of the HeartLogic heart failure diagnostic feature.
Eligibility criteria
Qualifiers
Boston Scientific device with HeartLogic enabled
history of ACE-inhibitor induced angioedema and in those with angiotensin II receptor blocker (ARB) therapy induced angioedema.
hypotension, hypovolemia
renal artery stenosis, renal failure
Disqualifiers
Glomerular filtration rate <25 mL/min who are non-responsive to diuretic therapy or are on chronic renal dialysis
ongoing symptoms of heart failure decompensation (increased dyspnea and/or fatigue, for purposes of this study increased weight is not considered, see question 2 KCCQ).
recent significant change in arrhythmia burden (within the past 2 weeks)
in cardiac resynchronization therapy (CRT) patients, recent change (60 days) in effective delivery of CRT (eg. decreased biventricular paving %)
Trial design
Treatments tested in this trial
- Furosemide
- Torsemide
- Bumetanide
- sacubitril/valsartan
- Hydralazine
- Isosorbide Dinitrate
Treatment groups
80 Participants
are divided into 3 treatment groupsSponsors and collaborators
Heart Center Research, LLC
Lead sponsor
Boston Scientific Corporation
Collaborator
Source ClinicalTrials.gov